Sir-Celecoxib is a widely used nonsteroidal antiinflammatory agent that acts through selective inhibition of COX-2. Here we demonstrate that celecoxib also significantly increases nuclear localization of the glucocorticoid receptor (GR), increases GR binding to its DNA responsive element and enhances GRmediated gene transcription in association with inhibition of p38 MAP kinase. These results expand the intracellular targets of COX-2 inhibitors while widening their potential clinical application to multiple disorders associated with impaired GR function including major depression.
Glucocorticoids play an essential role in shaping and eventually restraining physiological responses to environmental stressors, including early, innate, immune responses (inflammation); activation of the sympathetic nervous system and stimulation of neuroendocrine pathways, all of which are capable of producing a host of adverse health outcomes if allowed to continue unabated after stressor cessation. 1 A number of diseases including certain autoimmune, infectious and inflammatory disorders as well as a subgroup of neuropsychiatric disorders such as major depression have been associated with decreased responsiveness to glucocorticoids and impaired functioning of the GR. 2, 3 One potential mediator of disrupted GR function in these diseases is proinflammatory cytokines. 3 Each of these disorders has been characterized by increased circulating and/or tissue expression of proinflammatory cytokines. Moreover, proinflammatory cytokines through their signaling pathways have been found to negatively regulate GR function. For example, IL-1 alpha activation of p38 MAPK pathways has been shown to decrease GR DNA binding and GR-mediated gene transcription. 4 Similar decreases in GR activity have been found following activation of JNK and NF-kB inflammatory signaling pathways. 5, 6 In this study, rat neuronal PC12 cells stably transfected with MMTV-luciferase construct were used to investigate the direct impact of COX inhibition on GR function. Treatment of cells with the selective COX-2 inhibitor, celecoxib, caused significant dose-dependent induction of GR-mediated luciferase activity at both 5 and 24 h of treatment ( Figure   1a ). Similar results were found with the nonselective COX inhibitor, ibuprofen (100-1000 mM). Interestingly, valerylsalicylic acid, a COX-1 selective inhibitor, had no effects on GR-mediated luciferase activity, indicating that the effects of COX inhibition on GR function are COX-2 specific. To determine the GR specificity of the effects of celecoxib on luciferase activity, we cotreated PC12 cells with celecoxib and the GR antagonist, RU486 (40 mM), alone and in combination, for 5 h (data not shown). RU486 significantly reduced the effects of celecoxib on GR-mediated luciferase activity (32% decrease, n ¼ 3 per group, Po0.05 using Newman-Keuls Multiple Comparison Test), although, as has been previously reported, RU486 alone induced a mild increase in GR function. 7 The GR is primarily located in cytosol under basal conditions and its nuclear accumulation is essential for GR DNA binding and/or interaction with other relevant transcription factors. We therefore probed GR protein in nuclear extracts of cells treated with celecoxib with or without cotreatment with the synthetic glucocorticoid, dexamethasone (Dex). As seen in Figure 1b , celecoxib caused a noticeable increase of GR nuclear localization both alone and in combination with Dex. Of note, GR nuclear localization was accompanied by evidence of increased binding of the GR to its DNA glucocorticoid responsive element (GRE) as determined by electrophoretic mobility shift assay (EMSA) (Figure 1c) . A significant increase in GR-GRE binding was also observed as a result of celecoxib (Cbx) treatment using the TansAM GR transcription factor assay (Active Motif, Carlsbad, CA, USA) (mean absorbance: control 177.7 (SD 4.0); Cbx 50 mM 5 h 227.8 (SD 15.4); Cbx 50 mM 24 h 252.0 (SD 15.4); Dex 10 nM 2 h 348.7 (SD 20.1), F(3,8) ¼ 69.0, Po0.001). As certain COX inhibitors have also been reported to inhibit p38 MAPK, 8 to explore the molecular mechanism of COX-2 inhibitormediated GR function enhancement, we investigated the direct effects of celecoxib on p38 MAPK. Results in Figure 1d show that celecoxib alone (50 mM) caused significant reduction of phosphorylated p38 MAPK. To further investigate p38 involvem ent, a selective p38 activator, anisomycin, was employed. Anisomycin (50 ng/ml) showed strong time-dependent induction of p38 phosphorylation (Figure 1d ). Moreover, results showed that cotreatment with anisomycin significantly reversed celecoxib's effect on GR function ( Figure 1a) . The results of this study are the first to show that a widely used selective COX-2 inhibitor, celecoxib, induces GR nuclear localization and enhances GR-mediated gene transcription. Celecoxib's positive effect on GR function appears to be through inhibition of p38 MAPK. The data from this study suggest that inhibition of COX pathways may represent a therapeutic target for normalization of GR function in disorders characterized by reduced responsiveness to glucocorticoids. Interestingly, aside from its relevance to inflammatory disorders, reduced responsiveness to glucocorticoids is commonly seen in neuropsychiatric disorders including, most notably, major depression. These data suggest that COX-2 inhibitors may represent novel therapeutic agents for the treatment of depression. Indeed, like celecoxib, antidepressant agents have been shown to translocate the GR and increase GR-mediated gene transcription. 9 Given the negative impact of inflammatory signaling pathways including p38 and COX-2 on long-term potentiation (LTP) 10 and neurogenesis, 11 inhibition of COX-2 may represent a unique approach to multiple pathophysiologic targets, including, but not limited to the GR, in affective disorders. Figure 1 (a) PC12 cells stably transfected with an MMTVluciferase construct were grown in 12-well culture plates to 80% confluency and treated with celecoxib (Cbx) and anisomycin (Anis) alone or in combination at the concentrations indicated. Cells treated with anisomycin plus celecoxib were incubated for 1 h with anisomycin prior to addition of celecoxib. Cells were harvested after 5 h incubation, and luciferase activity was assessed. Each data point represents the mean7SE from at least three separate experiments. **Indicates Po0.001 compared to control, þ þ Indicates Po0.001 compared to Cbx alone. (b) To assess GR nuclear translocation, PC12 cells were treated with celecoxib (50 mM) for 5 h in the presence or absence of Dex (10 nM, 2 h). Nuclear extracts (25 mg) from each treatment group were analyzed by Western blot using a GR antibody from ABR-Affinity BioReagents (Golden, CO, USA). Nuclear extracts were obtained by resuspending nuclear pellets in high-salt buffer (20 mM HEPES, pH 7.9, 420 mM NaCl, 10 mM KCl, 0.1 mM Na 3 VO 4 , 1 mM EDTA, 1 mM EGTA, 20% glycerol, 0.5 mM PMSF and 1 mM DTT) and vigorously rocking for 30 min at 41C. Nuclear extracts were then collected after centrifugation for 30 min at 48 000 rpm (41C). GR-glucocorticoid receptor. Actin was used as a loading control. (c) The effect of celecoxib (50 mM) on GR-GRE binding was examined in 10 mg nuclear extracts (prepared as above) from PC12 cells using EMSA and 32 Plabeled synthetic double-strand GRE oligonucleotides (5 0 -AAG ATT CAG GTC ATG ACC TGA GGA GA). Data are from a representative experiment of three separate experiments. (d) To examine the effects of treatments on p38 MAPK, total cell extracts were isolated after cells were treated with celecoxib (50 mM) and/or anisomycin (50 ng/ml) as indicated. Protein (50 mg) from each treatment group was analyzed by Western blot using a monoclonal antibody against phosphorylated p38 MAPK. SIR-Recently, Hamilton et al 1 performed a genomewide scan in 60 multiplex pedigrees with a 'panic disorder syndrome' and found the most convincing linkage evidence on 13q32-q33. This chromosomal region has received strong attention in the study of schizophrenia and bipolar affective disorder (BPAD), since genetic variants within or near to the overlapping genes D-amino-acid oxidase activator (DAOA) and G30 located on 13q33 were associated with both schizophrenia and BPAD. [2] [3] [4] In this study, we hypothesized that the DAOA/G30 locus might also confer risk for the development of panic disorder (PD). Several lines of evidence support this hypothesis: firstly, DAOA/G30 is located within the linkage peak for panic disorder syndrome observed by Hamilton et al. 1 Secondly, results of several clinical and epidemiological studies suggest a shared etiologic background between PD and schizophrenia, for example, Bayle et al, 5 as well as between PD and BPAD, for example, MacKinnon et al. 6 Thirdly, recent findings suggest the involvement of DAOA in the glutamatergic signaling pathway, 2 a pathway that has been implicated in anxiogenesis.
We analyzed SNPs at the DAOA/G30 locus in a sample consisting of 152 patients with PD and 208 controls of German descent. Patients were diagnosed according to DSM-IIIR and DSM-IV on the basis of structured clinical interviews (SADS-LA 7 and CIDI 8 ) and/or a review of medical records. The control individuals were anonymous blood donors, who had been recruited independently from the controls used in our previous association study of schizophrenia and BPAD. 4 We focused on SNPs rs2391191 (M15), rs3918342 (M23), and rs421292 (M24), as these had shown the strongest association in our previous work. 4 Additionally, we typed two flanking SNPs, rs778293 (M22) and rs3916972 (M25), covering this chromosomal region. Genotyping was carried out using the MassARRAY system (Sequenom, San Diego, USA) according to the genotyping method described by Ding and Cantor, 9 with minor modifications (see Supplementary table) . We performed both singlemarker and haplotype analyses with the program COCAPHASE 2.40. 10 Of the five variants at the DAOA/G30 locus typed, three SNPs (rs778293, rs3918342, and rs1421292) proved to be in significant LD with PD (Table 1) , with the strongest evidence being observed for rs1421292 (P ¼ 0.031, OR 1.39). At the genotypic level, significant association was found between PD patients and rs1421292 under a dominant model (P ¼ 0.024, OR 2.12, Table 1 ). Given that a Bonferroni correction to adjust for multiple testing of loci would be overly conservative, and given the high levels of LD of these closely related markers, we used a permutation procedure instead. Our best P-value in the allelewise analysis was 0.031. In our simulation, a P-value of 0.031 or smaller would be seen by chance alone in 1129 times out of 10 000 replicates, yielding an empirical P-value of 0.113. In a subsequent step, we performed haplotype analysis (data not shown) comprising SNPs rs778293, rs3918342, and rs1421292, which were associated with disease in the single-locus analysis. The three-marker haplotype T-T-A was significantly less frequent in patients with PD (40 vs 48% in controls, P ¼ 0.030), and the haplotype C-C-T was more frequent in PD patients (42 vs 35% in controls, P ¼ 0.072). Although far from being significant (P-values 40.1), it is interesting to note that the allelic and haplotypic associations seem to be stronger in PD than in schizophrenia and BPAD. For example, the same alleles of rs3918342 and rs1421292 previously shown to be associated with schizophrenia and BPAD 4 were even more frequent in patients with PD (rs3918342 allele C: 53% in schizophrenia and BPAD, 4 57% in PD; rs1421292 allele T: 56 and 55% in schizophrenia and BPAD, 4 respectively, 60% in PD).
Despite the fact that the observed single-marker associations do not withstand a stringent and robust adjustment for multiple testing at a nominal level of significance, our results suggest that variability at the DAOA/G30 locus may be involved in the etiology of PD. Since we have previously observed the same alleles and haplotypes to be associated with disease in our study on BPAD and schizophrenia, we believe that our findings are of potential interest for the psychiatric genetic community and may give a new perspective on conventional diagnostic categories.
